公开(公告)号：US20230054250A1

公开(公告)日：2023-02-23

申请号：US17792499

申请日：2021-01-14

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Yong GAN ,  Shiyan GUO ,  Yinyin SUN

IPC: A61K9/127 ,  A61K31/167 ,  A61K31/277 ,  A61K31/5415 ,  A61K31/4748 ,  A61K31/445 ,  A61K31/138 ,  A61K31/475 ,  A61K31/4365 ,  A61K31/245 ,  A61K31/366 ,  A61K31/4422 ,  A61K47/10 ,  A61K47/24 ,  A61K47/14 ,  A61K47/44 ,  A61K47/28 ,  A61K9/00

Abstract: A non-aqueous sustained release drug delivery system, which contains, based on the total weight of the sustained release drug delivery system, about 0.1-20% of an active agent, about 0.5-50% of a drug solvent, about 1-98% of a drug sustained release agent, about 0.1-85% of a drug solubilizer, about 0.1-10% of an efficacy enhancer, about 0-1% of an antioxidant, and about 0-8% of an acid-base regulator. The non-aqueous sustained release drug delivery system can yield an improved sustained release effect, improve bioavailability, and enhance the therapeutic effect.

公开(公告)号：US20250090547A1

公开(公告)日：2025-03-20

申请号：US18724128

申请日：2023-02-28

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Yong GAN ,  Xinxin ZHANG ,  Linmiao GUO ,  Yunqiu MIAO ,  Xiaoli WANG ,  Ying ZHANG ,  Chunliu ZHU

IPC: A61K31/557 ,  A61K9/00 ,  A61K9/107 ,  A61K47/24

Abstract: The present application relates to an EPA-EE nano-lipid composition and a formulation, a preparation method, and an application thereof. The EPA-EE nano-lipid composition includes a raw material having a high content of EPA-EE as a primary ingredient and includes an emulsifier containing a highly unsaturated phospholipid. The EPA-EE nano-lipid composition can be prepared into a sub-micron emulsion at nanoscale for use as an oral formulation.

公开(公告)号：US20240261391A1

公开(公告)日：2024-08-08

申请号：US18565013

申请日：2022-05-30

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SHENZHEN UNIVERSITY

Inventor： Xinxin ZHANG ,  Likun GONG ,  Jin REN ,  Guangyi JIN ,  Wei HUANG ,  Yong GAN ,  Jianhua SUN ,  Tingting LIU ,  Yiru LONG ,  Yunqiu MIAO ,  Qiuping QIN ,  Feng TANG ,  Pan YU ,  Linmiao GUO

IPC: A61K39/215 ,  A61K39/00 ,  A61K47/22 ,  C12N7/00

CPC classification number: A61K39/215 ,  A61K47/22 ,  C12N7/00 ,  A61K2039/55566 ,  C12N2770/20034

Abstract: The present invention relates to a novel coronavirus vaccine using a TLR7 agonist conjugated peptide as an antigen and an emulsion as an adjuvant. An antigen polypeptide of the conjugated peptide is a polypeptide derived from an S protein of SARS-COV-2, and the adjuvant is an oil-in-water nanoemulsion containing squalene. The conjugated peptide nanoemulsion vaccine preparation of the present invention is thermally stable, and can induce a high level of protective humoral immune response in a cynomolgus monkey, and the neutralizing antibody titer of antiserum after immunization of cynomolgus monkey is high, such that invasion of wild-type strain and mutant novel coronavirus can be blocked. The vaccine of the present invention has a nearly complete protection effect on the upper and lower respiratory tracts of the cynomolgus monkey in a cynomolgus monkey SARS-COV-2 challenge test. The nanoemulsion vaccine of the present invention is fast and convenient to prepare, and can realize large-scale production in a short term for coping with the novel coronavirus outbreak.

公开(公告)号：US20250009871A1

公开(公告)日：2025-01-09

申请号：US18564932

申请日：2022-05-30

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES

Inventor： Likun GONG ,  Jin REN ,  Wei HUANG ,  Yong GAN ,  Yongtang ZHENG ,  Jianhua SUN ,  Xinxin ZHANG ,  Yiru LONG ,  Qiuping QIN ,  Tingting LIU ,  Feng TANG ,  Pan YU ,  Yunqiu MIAO ,  Yonglong CAI ,  Mian QIN ,  Tianzhang SONG

IPC: A61K39/215 ,  A61K9/107 ,  A61P37/04 ,  C07K14/005

Abstract: Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains.

公开(公告)号：US20230080811A1

公开(公告)日：2023-03-16

申请号：US17792474

申请日：2021-01-14

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Yong GAN ,  Shiyan GUO ,  Yinyin SUN ,  Quanlei ZHU

IPC: A61K47/24 ,  A61K31/445 ,  A61K47/44 ,  A61K47/12 ,  A61K9/08 ,  A61P23/02

Abstract: Provided are a long-acting ropivacaine pharmaceutical composition, a preparation method therefor and use thereof. The pharmaceutical composition comprises: ropivacaine; a pharmaceutical solvent; a pharmaceutical phospholipid; a pharmaceutical oil; and an efficacy enhancer, an optional antioxidant and an optional acid-base regulator. The pharmaceutical composition has a controllable release behavior and a sustained release effect, can significantly reduce the peak plasma concentration of the drug, maintain a stable plasma concentration in the body, prolong the effective treatment time, reduce the effective therapeutic dose, improve the utilization of the drug, and reduce the risk of neurotoxicity. The pharmaceutical composition has a long-acting analgesic effect and can be used for pain treatment.

公开(公告)号：US20180133215A1

公开(公告)日：2018-05-17

申请号：US15574557

申请日：2016-05-13

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  Shanghai Acebright Pharmaceuticals Co., Ltd.

Inventor： Shiyan GUO ,  Yong GAN ,  Ao ZHANG ,  Zehong MIAO ,  Li GAO ,  Jian DING

IPC: A61K31/502 ,  A61K47/40 ,  A61K47/38 ,  A61K47/34 ,  A61K47/32 ,  A61K9/48 ,  A61K9/28 ,  A61P35/00

CPC classification number: A61K31/502 ,  A61K9/08 ,  A61K9/10 ,  A61K9/146 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/28 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/10 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A61K47/40 ,  A61P35/00

Abstract: Disclosed is an SOMCL-9112 solid dispersion. The SOMCL-9112 solid dispersion is characterized by being prepared from the following raw materials in percentage by weight: 5 percent to 60 percent of SOMCL-9112, 5 percent to 90 percent of pharmaceutically acceptable matrix polymer, 0 percent to 20 percent of surfactant, 0 percent to 20 percent of flow aid and 0 percent to 20 percent of plasticizer. Also disclosed are a preparation method of the SOMCL-9112 solid dispersion, a solid medicinal preparation containing the solid dispersion and application of the solid dispersion for preparing a medicine for treating cancer.